Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • USA bans Indian...

    USA bans Indian drugmaker Divi's factory

    Written by supriya kashyap kashyap Published On 2017-03-23T11:17:32+05:30  |  Updated On 23 March 2017 11:17 AM IST

    US health regulators have banned a drug production site in India belonging to Divi's Laboratories Ltd due to manufacturing violations, sending the company's shares down to a near three-year low.


    This comes at a time when an increasingly protectionist stance by US President Donald Trump is threatening to make the operating environment tougher for India's drug makers that supply nearly a third of the medicines sold in the United States the world's largest healthcare market.


    The US Food and Drug Administration's ban on Divi's Unit II factory in Vizag news of which was posted on the FDA website and seen by Reuters on Wednesday is the second setback this month for India's drugs industry.


    The FDA found violations of manufacturing standards at Dr Reddy's Laboratories Ltd's drug plant, also in Vizag, during an inspection that ended on March 8, according to a copy of the inspection report seen by Reuters on Wednesday.


    Several analysts downgraded Divi's stock to "sell" and others such as Jefferies maintained their "underperform" rating on Reddy's stock, citing increasing regulatory challenges.


    About 70 per cent of Divi's total sales that depend on the plant are now under threat as other countries may go after the factory, prompted by the FDA action, said Edelweiss analysts.


    Divi's did not respond to an email requesting comment on Wednesday, but said in a statement to exchanges that it had started necessary measures to address the FDA's concerns.


    Shares in the company have plunged 18 per cent this week and were mired near a three-year low of 611.45 rupees ($9.34) on Wednesday. Dr. Reddy's stock hit 2,555.20 rupees earlier the day, also their lowest since 2014.


    REDDY'S REPEAT VIOLATIONS


    Dr Reddy's told Reuters it plans to submit "a comprehensive response" to the FDA, which said it had found multiple repeat violations at the site - including problems that the agency had notified the company of as far back as in 2015. Issues listed in the report included data manipulation, as well as a Dr Reddy's employee lying to FDA inspectors.


    "We are confident in our ability to address these observations and will work with US FDA in resolving these issues," Dr Reddy's Chief Financial Officer Saumen Chakraborty said in an emailed statement.


    Analysts, however, say the FDA report could be a risk for Dr Reddy's all-important oncology pipeline, which has been a key area of focus for the company as it looks to improve its business in the United States, its largest market.


    "These (FDA) observations significantly increase the risk of delay in resolution of Srikakulam facility also," Jefferies analysts said in a report on Tuesday, referring to another Dr Reddy's plant that is under scrutiny.


    The FDA has banned more than 40 Indian factories in recent years over quality control failures and manipulation of data.


    Companies say they have been working on improving their processes, but major issues continue to be found at some of India's biggest drug makers, dealing a blow to the industry's image as a reliable supplier of cheap generic medicines.

    Divi'sDonald TrumpDr Reddy'sgenericSaumen ChakrabortyUS Food and Drug AdministrationUSFDA
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok